SCHEMBL6791928

SCHEMBL6791928

CCCCCCN(C)c1ccc(/C=C2\SC(=S)N(CS(=O)(=O)O)C2=O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DNM1 Q05193 2/20 0.48
▸ ALDH1A1 P00352 3/20 0.45
▸ MAOA P21397 1/20 0.45
▸ MAOB P27338 1/20 0.45
▸ CRHBP P24387 1/20 0.45
▸ CRHR2 Q13324 1/20 0.45
▸ MCHR1 Q99705 1/20 0.44
▸ MYC P01106 2/20 0.43
▸ MAX P61244 2/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ THRB P10828 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ PAX8 Q06710 1/20 0.42
▸ MAPK1 P28482 3/20 0.41
▸ MAPT P10636 2/20 0.41
▸ PTPN12 Q05209 1/20 0.41
▸ PTPN22 Q9Y2R2 1/20 0.41
▸ MITF O75030 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6788428 1.00 DNM1 (0.48) DNM1ALDH1A1MAOAMAOBCRHBP
SCHEMBL6785809 0.90 ALDH1A1 (0.48) DNM1ALDH1A1MAOAMAOBCRHBP
SCHEMBL6785812 0.90 ALDH1A1 (0.48) DNM1ALDH1A1MAOAMAOBCRHBP
SCHEMBL7484741 0.85 PTPN12 (0.60) ALDH1A1NPSR1KMT2AKDM4EHPGD
SCHEMBL7484747 0.85 PTPN12 (0.60) ALDH1A1NPSR1KMT2AKDM4EHPGD
SCHEMBL6791768 0.85 PTPN12 (0.60) ALDH1A1NPSR1KMT2AKDM4EHPGD
SCHEMBL6791775 0.85 PTPN12 (0.60) ALDH1A1NPSR1KMT2AKDM4EHPGD
SCHEMBL6792514 0.84 MAPK1 (0.60) DNM1ALDH1A1MAOAMAOBCRHBP
SCHEMBL6792516 0.84 MAPK1 (0.60) DNM1ALDH1A1MAOAMAOBCRHBP
SCHEMBL7486836 0.83 CISD1 (0.62) ALDH1A1MAOAMYCMAXKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1192144-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2002-04-03 — — EP claimed
WO-2000076988-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2000-12-21 — — WO claimed
US-20040197268-A1 Method of imaging amyloid deposits using substituted rhodanine derivatives AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-10-07 — — US disclosed
EP-1192144-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2002-04-03 — — EP disclosed
WO-2000076988-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2000-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040197268-A1 Method of imaging amyloid deposits using substituted rhodanine derivatives APP, PSEN1, PSEN2 DNM1 543/4885ALDH1A1 1741/4885MAOA 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback